Table 1.
Characteristics | N=1237 |
---|---|
Age (years) | 48.9±13.4 |
Sex | |
Male | 217 (17.5%) |
Female | 1020 (82.5%) |
Occupation | |
Persons in charge of party organizations, state organizations, mass organizations, social organizations, enterprises, and institutions | 124 (10.0%) |
Professionals | 109 (8.8%) |
Clerks | 85 (6.9%) |
Service staff | 148 (12.0%) |
Agricultural, forestry, animal husbandry, fisheries, and auxiliary personnel | 183 (14.8%) |
Manufacturing and related personnel | 39 (3.2%) |
Soldier | 1 (0.1%) |
Others | 548 (44.3%) |
Education Level | |
Junior high school or below | 555 (44.9%) |
Senior high school | 342 (27.6%) |
College | 312 (25.2%) |
Master degree or above | 28 (2.3%) |
Duration of Rheumatoid Arthritis (Years) | |
<2 | 385 (31.1%) |
2–5 | 358 (28.9%) |
6–10 | 218 (17.6%) |
>10 | 276 (22.3%) |
Severity of the Disease Assessed by the Patient | |
Severe | 230 (18.6%) |
Moderate | 543 (43.9%) |
Mild | 425 (34.4%) |
Extremely mild | 39 (3.2%) |
DAS28-ESR | 4.2±1.7 |
DAS28-CRP | 3.7±1.6 |
PtGA | 4.29±2.52 |
Current Medication | |
csDMARDs | 1037 (83.8%) |
Glucocorticoids | 488 (39.5%) |
bDMARDs | 202 (16.3%) |
Communication with Physicians | |
Full communication | 818 (66.1%) |
Good communication, but a little hasty | 247 (20.0%) |
Average communication level and can get the information | 98 (7.9%) |
Less communication with physicians | 60 (4.9%) |
Basically no communication | 14 (1.1%) |
Cost of Treatment for Rheumatoid Arthritis, Proportion of Household Income (%) | |
<10 | 442 (35.7%) |
10–30 | 274 (22.2%) |
31–50 | 264 (21.3%) |
>50 | 257 (20.8%) |
Satisfaction Towards General Diagnostic and Treatment Services | |
Extremely satisfied | 745 (60.2%) |
Very satisfied | 287 (23.2%) |
Satisfied | 109 (8.8%) |
Somewhat satisfied | 79 (6.4%) |
Not quite satisfied | 6 (0.5%) |
Dissatisfied | 3 (0.2%) |
Extremely dissatisfied | 8 (0.7%) |
Note: Data are expressed as mean±standard deviation or n (%).
Abbreviations: bDMARDs, biological disease-modifying antirheumatic drugs; csDMARDS, conventional synthetic disease-modifying antirheumatic drugs; DAS28-ESR, disease activity score 28-erythrocyte sedimentation rate; DAS28-CRP, disease activity score 28-C-reactive protein; PtGA, patient global assessment of disease activity.